Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment (Q57151323)

From Wikidata
Jump to navigation Jump to search
scientific article published on 27 September 2011
edit
Language Label Description Also known as
English
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
scientific article published on 27 September 2011

    Statements

    title
    Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment (English)
    1 reference
    stated in
    Europe PubMed Central
    PubMed publication ID
    21951682
    reference URL
    https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21951682%20AND%20SRC:MED&resulttype=core&format=json
    retrieved
    13 February 2020
    author
    author name string

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q57151323&oldid=1811994683"